Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board
January 24, 2023
Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
January 17, 2023
Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases
December 13, 2022
Beyond Air® To Participate in Piper’s 34th Annual Healthcare Conference
November 17, 2022
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 10, 2022
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
November 8, 2022
Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
October 24, 2022
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast
October 20, 2022
Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022
October 17, 2022
Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting
October 5, 2022

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe